Evoke Wealth’s AnaptysBio ANAB Stock Holding History

Evoke Wealth’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-127	Closed	-$3K	–	392
2022 Q3	$3K	Hold	127	–	–	﹤0.01%	952
2022 Q2	$3K	Hold	127	–	–	﹤0.01%	964
2022 Q1	$3K	Hold	127	–	–	﹤0.01%	977
2021 Q4	$4K	Hold	127	–	–	﹤0.01%	923
2021 Q3	$3K	Hold	127	–	–	﹤0.01%	925
2021 Q2	$3K	Hold	127	–	–	﹤0.01%	966
2021 Q1	$3K	Hold	127	–	–	﹤0.01%	927
2020 Q4	$3K	Hold	127	–	–	﹤0.01%	806
2020 Q3	$2K	Hold	127	–	–	﹤0.01%	819
2020 Q2	$3K	Hold	127	–	–	﹤0.01%	769
2020 Q1	$1.79K	Hold	127	–	–	﹤0.01%	818
2019 Q4	$2.06K	Buy	+127	New	+$3K	﹤0.01%	1062

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Evoke Wealth's ANAB Position: Q4 2022 in Review

Evoke Wealth sold out of AnaptysBio (ANAB) in Q4 2022, closing a stake of 127 shares — an estimated $3K sold.

Evoke Wealth first reported a position in ANAB in Q4 2019 and held it in 12 quarters. The position peaked at $4K in Q4 2021. 118 funds tracked by Wall St. Rank hold ANAB as of Q4 2022.

Evoke Wealth reported no remaining AnaptysBio position as of Q4 2022 after selling out during the quarter.
Evoke Wealth sold 127 AnaptysBio shares in Q4 2022, an estimated $3K.
Evoke Wealth first reported a position in AnaptysBio in Q4 2019 and held it in 12 quarters.
Evoke Wealth's AnaptysBio position peaked at $4K in Q4 2021.
118 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2022.

Based on Evoke Wealth's 13F filing for Q4 2022, filed 10 Feb 2023.